GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » QuidelOrtho Corp (NAS:QDEL) » Definitions » Altman Z-Score
中文

QuidelOrtho (QuidelOrtho) Altman Z-Score

: 1.29 (As of Today)
View and export this data going back to 1992. Start your Free Trial

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Warning Sign:

Altman Z-score of 1.29 is in distress zone. This implies bankruptcy possibility in the next two years.

QuidelOrtho has a Altman Z-Score of 1.29, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for QuidelOrtho's Altman Z-Score or its related term are showing as below:

QDEL' s Altman Z-Score Range Over the Past 10 Years
Min: 1.29   Med: 3.7   Max: 12.43
Current: 1.29

During the past 13 years, QuidelOrtho's highest Altman Z-Score was 12.43. The lowest was 1.29. And the median was 3.70.


QuidelOrtho Altman Z-Score Historical Data

The historical data trend for QuidelOrtho's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

QuidelOrtho Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Altman Z-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.62 12.43 10.17 1.97 1.66

QuidelOrtho Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.97 1.84 1.82 1.69 1.66

Competitive Comparison

For the Medical Devices subindustry, QuidelOrtho's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


QuidelOrtho Altman Z-Score Distribution

For the Medical Devices & Instruments industry and Healthcare sector, QuidelOrtho's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where QuidelOrtho's Altman Z-Score falls into.



QuidelOrtho Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

QuidelOrtho's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*0.0557+1.4*0.2555+3.3*0.0175+0.6*0.7599+1.0*0.3501
=1.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Dec. 2023:
Total Assets was $8,563 Mil.
Total Current Assets was $1,311 Mil.
Total Current Liabilities was $834 Mil.
Retained Earnings was $2,188 Mil.
Pre-Tax Income was -9.2 + -15.5 + -64.4 + 60 = $-29 Mil.
Interest Expense was -46.2 + -46.6 + -44.7 + -41.4 = $-179 Mil.
Revenue was 742.6 + 744 + 665.1 + 846.1 = $2,998 Mil.
Market Cap (Today) was $2,703 Mil.
Total Liabilities was $3,557 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(1310.5 - 833.8)/8563.1
=0.0557

X2=Retained Earnings/Total Assets
=2187.8/8563.1
=0.2555

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-29.1 - -178.9)/8563.1
=0.0175

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=2703.236/3557.2
=0.7599

X5=Revenue/Total Assets
=2997.8/8563.1
=0.3501

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

QuidelOrtho has a Altman Z-Score of 1.29 indicating it is in Distress Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


QuidelOrtho  (NAS:QDEL) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


QuidelOrtho Altman Z-Score Related Terms

Thank you for viewing the detailed overview of QuidelOrtho's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


QuidelOrtho (QuidelOrtho) Business Description

Traded in Other Exchanges
Address
9975 Summers Ridge Road, San Diego, CA, USA, 92121
QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make better decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if the revenue from North America.
Executives
Louise Brandy officer: SVP, Chief Information Officer 9975 SUMMERS RIDGE ROAD, SAN DIEGO CA 92121
Patrick Klein officer: Chief Administrative Officer 9975 SUMMERS RIDGE ROAD, SAN DIEGO CA 92121
Christopher M Smith director 125 CONSTITUTION DRIVE, MENLO PARK CA 94025
Edward L. Michael director 618 SHERIDAN SQUARE, EVANSTON IL 60202
William J. Ferenczy officer: SVP, Cardio/Metabolic Unit 9975 SUMMERS RIDGE ROAD SAN DIEGO CA 92121
Werner Kroll officer: SVP, Research and Development 12544 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Kenneth F Buechler director
Robert R. Schmidt director C/O THE CARLYLE GROUP, SUITE 220 SOUTH, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004
Tamara A. Ranalli officer: SVP, Molecular Bus. Unit 9975 SUMMERS RIDGE ROAD SAN DIEGO CA 92121
Stephen H. Wise director C/O THE CARLYLE GROUP, SUITE 220 SOUTH, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004
Robert Joseph Bujarski officer: See Remarks C/O QUIDEL CORPORATION, 12544 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Wilkins Joseph D Jr. director 82414 PUCCINI DRIVE, INDIO CA 92203
Michelle A. Hodges officer: SVP, General Counsel 9975 SUMMERS RIDGE ROAD, SAN DIEGO CA 92121
Douglas C Bryant director, officer: Chairman & CEO C/O QUIDEL CORPORATION, 12544 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Joseph M Busky officer: Chief Financial Officer 1717 DEERFIELD ROAD, DEERFIELD IL 60015